Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

Abstract Background Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST). Methods This retrospective analysis compared efficacy of...

Full description

Bibliographic Details
Main Authors: Margaret von Mehren, Michael C. Heinrich, Hongliang Shi, Sergio Iannazzo, Raymond Mankoski, Saša Dimitrijević, Gerard Hoehn, Silvia Chiroli, Suzanne George
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
GIST
Avapritinib
PDGFRA D842V mutation
Online Access:https://doi.org/10.1186/s12885-021-08013-1

Internet

https://doi.org/10.1186/s12885-021-08013-1

Similar Items